Immunotherapy Monitoring

The development of methods to propagate immune T-cells, and in particular tumor specific T-cells from the patients with cancer, lead to an important breakthrough; the identification of MAGE-1,a melanoma-specific antigen that stimulates human T-cells in-vitro. With antigen specific T-cells as a reagents, it was possible to clone the MAGE-1 studies showed that the human immune system can respond tumor antigens, and the findings stimulated a productive effort to discover tumor antigens. The result is a long and still-growing list of antigens from a variety of tumor that could serve a variety of tumor’s that could serve as targets for treatment.

 

    Related Conference of Immunotherapy Monitoring

    July 29-30 2019

    6th International Conference on Parasitology & Microbiology

    Amsterdam, Netherlands
    July 29-30, 2019

    11th Global Summit on Immunology and Cell Biology

    Sydney, Australia
    November 12-13, 2019

    13th International Congress on Autoimmunity

    Brisbane, Australia
    November 14-15, 2019

    International Conference on Vaccines and Immune Response

    Istanbul, Turkey
    November 14-15, 2019

    Annual Congress on Antibiotics and Antimicrobial Resistance

    Geneva, Switzerland
    November 21-22, 2019

    World Conference on Vaccine and Immunology

    Dubai, UAE

    Immunotherapy Monitoring Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in